Catalysts About Viking Therapeutics Viking Therapeutics focuses on developing therapies for obesity and related cardiometabolic conditions, with VK2735 as its lead dual GLP-1 and GIP receptor agonist program in both injectable and oral forms. What are the underlying business or industry changes driving this perspective?Read more

ForFarmers is leaning on expansion in Eastern Europe, tighter cost control, and more sustainable feed products to grow even as livestock farming rules tighten across parts of Europe. The key question is whether it can keep gaining share through deals and partnerships without getting hit by farmer exits, tougher regulations, or volatile results from its joint ventures.Read more

Akebia’s Vafseo aims to replace the hassle of anemia shots in kidney disease with a pill that helps the body make its own blood-building signal and use iron better. The big swing isn’t just the science—it’s whether the largest dialysis chains decide to bake it into their standard treatment plans, quickly opening the door to many more patients.Read more

Netflix is leaning hard into ads, smarter recommendations, and more local shows to keep people watching longer and bring in new viewers around the world. The upside looks real, but rising content costs, tougher competition, and a shakier economy could still slow growth and profits.Read more

AMD may not be the biggest name in AI chips, but big cloud companies want a real backup to Nvidia and are backing AMD so they’re not stuck with one supplier. With new AI chips gaining traction and a growing role in data centers and edge devices, the company could see profits improve—but it still has to prove it can keep up.Read more

Coca-Cola keeps finding new ways to grow beyond soda, with momentum building in emerging markets, online ordering, and fast-growing dairy and “better-for-you” drinks. But shifting health preferences, tougher rules, and rising competition could make it harder to protect profits as costs and supply chains stay unpredictable.Read more

Microsoft is spending heavily on artificial intelligence, and the market seems to be punishing it more than similar big tech rivals. If the hype around these tools keeps driving demand, the company could rebound while still leaning on its many other businesses if that trend cools.Read more

MindWalk Holdings is no longer just a lab-for-hire business—it’s shifting into software that helps drug teams learn from biology data, and the market may not be treating it that way yet. The story hinges on whether its LensAI platform keeps landing sticky enterprise customers and whether its drug programs attract partners without forcing shareholders to fund the bill.Read more